Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2025 Financial Results PONTE VEDRA, Fla. – May 8, 2025 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2025 Recent Highlights "We are pleased with the positive c ...

Core Insights - Treace Medical Concepts, Inc. reported a revenue of $52.6 million for Q1 2025, a 3% increase from $51.1 million in Q1 2024, with an adjusted growth of 4.5% when accounting for one less selling day [4][9] - The company is focused on expanding its bunion treatment portfolio and has received positive customer feedback on new specialized bunion systems [3][4] - Treace aims for a full-year 2025 revenue guidance of $224 million to $230 million, indicating a growth of 7% to 10% compared to 2024 [8] Financial Performance - Gross profit for Q1 2025 was $41.9 million, with a gross margin of 79.7%, slightly down from 80.2% in Q1 2024 [4] - Total operating expenses decreased to $57.5 million in Q1 2025 from $59.9 million in Q1 2024 [5] - The net loss for Q1 2025 was $(15.9) million, an improvement from $(18.7) million in Q1 2024, with adjusted EBITDA improving by 53% to $(3.8) million [6][9] Product Development and Market Position - Treace has expanded its bunion technology portfolio with new systems, including the Nanoplasty™ and Percuplasty™ 3D MIS Osteotomy Systems, and the SpeedMTP™ MTP Fusion System [9] - The company announced positive interim clinical data for its procedures at the 2025 ACFAS Annual Scientific Conference [9] - Treace's global patent portfolio has surpassed 100 granted patents, with 172 pending applications, indicating strong innovation and market positioning [9] Liquidity and Financial Outlook - As of March 31, 2025, Treace had total liquidity of $98.6 million, consisting of $76.1 million in cash and marketable securities, and $22.5 million available under a revolving loan facility [7] - The company continues to expect breakeven adjusted EBITDA for the full year 2025, reflecting a focus on improving operational efficiency [8]

Core Points - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit for shareholders who purchased shares during the class period from May 8, 2023, to May 7, 2024 [1] - Allegations in the complaint include that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," faced competition that negatively impacted demand and utilization, leading to a decline in revenue [1] - The company was required to accelerate plans for an alternative product to osteotomy due to the decline in revenue, and the defendants' positive statements about the company's business were misleading [1] Shareholder Information - Shareholders are encouraged to register for the class action by June 10, 2025, to potentially be appointed as lead plaintiff [2] - Registration allows shareholders to enroll in a portfolio monitoring software for status updates throughout the case lifecycle [2] Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Company Performance - The lawsuit claims that competition negatively affected the demand and utilization of Treace Medical's primary product, leading to a decline in revenue [3]. - The company was required to expedite plans for an alternative product to osteotomy due to the declining performance of its existing offerings [3]. Legal Proceedings - The class period for the lawsuit is defined as May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline set for June 10, 2025 [4]. Investor Information - The Gross Law Firm is representing the shareholders and aims to protect the rights of investors who have suffered losses due to the alleged misleading statements by Treace Medical [5]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose critical information regarding its business performance and product demand during the specified class period [3]. Group 1: Lawsuit Details - The class action lawsuit represents investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024 [1]. - Investors have until June 10, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that increased competition negatively impacted the demand for Treace Medical's core product, the Lapiplasty® 3D Bunion Correction System [3]. Group 2: Financial Impact - As a result of the competition, Treace Medical experienced a decline in revenue and was forced to expedite the development of an alternative product to osteotomy [3]. - The lawsuit alleges that the defendants made materially misleading representations about Treace Medical's business operations and future prospects, leading to investor damages when the true facts emerged [3]. Group 3: Legal Support - The Portnoy Law Firm offers complimentary case evaluations for investors seeking to recover losses and provides options for pursuing claims [2][4]. - The firm's founding partner has successfully recovered over $5.5 billion for aggrieved investors in the past [4].

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a ...

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," faced decreased demand due to competition [2]. - It is alleged that Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [2]. - Defendants are accused of making misleading positive statements regarding the company's business and prospects, lacking a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

If you purchased or acquired Treace Medical securities, and/or would like to discuss your legal rights and options please visit Treace Medical Concepts, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. According to the Complaint, Defendants made misrepresentations concerning the impact of competition on demand for, and utilization of, the Company's primary product, the Lapiplasty 3D Bunion Correction System. If you wish to ...

Group 1 - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) regarding a class action lawsuit for shareholders who purchased shares during the class period from May 8, 2023, to May 7, 2024 [1] - The allegations in the complaint include that competition negatively affected the demand for Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty," leading to a decline in revenue [1] - The company was required to accelerate plans to introduce an alternative product to osteotomy due to the decline in revenue and the misleading positive statements made by the defendants regarding the company's business and prospects [1] Group 2 - Shareholders are encouraged to register for the class action by June 10, 2025, to potentially become lead plaintiffs and participate in the case without any cost or obligation [2] - Once registered, shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [3]

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc." or the "Company") (NASDAQ: TMCI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Treace Medical Concepts, Inc. investors who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team: htt ...